683 Capital Management’s Redhill Biopharma RDHL Stock Holding History

683 Capital Management’s Portfolio RDHL Stock Details RDHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,035	Closed	-$6.28M	–	172
2019 Q4	$6.28M	Sell	1,035 -2,441	-70%	-$15.6M	0.72%	33
2019 Q3	$24.5M	Sell	3,476 -218	-6%	-$1.59M	2.72%	8
2019 Q2	$24M	Hold	3,694	–	–	2.18%	10
2019 Q1	$30.7M	Hold	3,694	–	–	2.78%	6
2018 Q4	$20.5M	Buy	3,694 +63	+2%	+$483K	1.24%	17
2018 Q3	$32.1M	Buy	3,631 +1,588	+78%	+$12.9M	2.08%	10
2018 Q2	$17.4M	Buy	2,043 +379	+23%	+$2.41M	1.18%	20
2018 Q1	$8.57M	Buy	1,664 +665	+67%	+$3.83M	0.76%	38
2017 Q4	$5.14M	Buy	+999	New	+$6.73M	0.43%	63

Other funds holding RDHL

Ibex Investors Denver, Colorado $194M AUM 23.58% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $5.91B AUM 53.97% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Creative Planning Overland Park, Kansas $171B AUM 24.68% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

Gagnon Securities New York $519M AUM 44.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

683 Capital Management's RDHL Position: Q1 2020 in Review

683 Capital Management sold out of Redhill Biopharma (RDHL) in Q1 2020, closing a stake of 1,035 shares — an estimated $6.28M sold.

683 Capital Management first reported a position in RDHL in Q4 2017 and held it in 9 quarters. The position peaked at $32.1M in Q3 2018. 46 funds tracked by Wall St. Rank hold RDHL as of Q1 2020.

683 Capital Management reported no remaining Redhill Biopharma position as of Q1 2020 after selling out during the quarter.
683 Capital Management sold 1,035 Redhill Biopharma shares in Q1 2020, an estimated $6.28M.
683 Capital Management first reported a position in Redhill Biopharma in Q4 2017 and held it in 9 quarters.
683 Capital Management's Redhill Biopharma position peaked at $32.1M in Q3 2018.
46 funds tracked by Wall St. Rank held Redhill Biopharma as of Q1 2020.

Based on 683 Capital Management's 13F filing for Q1 2020, filed 15 May 2020.